These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 8286188

  • 1. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ, Abel G, Kelland LR, Harrap KR.
    Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
    [Abstract] [Full Text] [Related]

  • 2. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR.
    Cancer Res; 1992 Nov 15; 52(22):6188-93. PubMed ID: 1423261
    [Abstract] [Full Text] [Related]

  • 3. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR.
    Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660
    [Abstract] [Full Text] [Related]

  • 4. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF, Hunakova L, Kelland LR.
    Chem Biol Interact; 1999 Nov 15; 123(1):11-29. PubMed ID: 10597899
    [Abstract] [Full Text] [Related]

  • 5. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep 15; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 6. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Aug 15; 68(2):240-50. PubMed ID: 8347478
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ, Kelland LR.
    Cancer Res; 1994 Dec 01; 54(23):6194-200. PubMed ID: 7954466
    [Abstract] [Full Text] [Related]

  • 8. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ, Barnard CF, Kelland LR, Harrap KR.
    Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906
    [Abstract] [Full Text] [Related]

  • 9. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    Mellish KJ, Barnard CF, Murrer BA, Kelland LR.
    Int J Cancer; 1995 Sep 15; 62(6):717-23. PubMed ID: 7558420
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Orr RM, O'Neill CF, Nicolson MC, Barnard CF, Murrer BA, Giandomenico CM, Vollano JF, Harrap KR.
    Br J Cancer; 1994 Sep 15; 70(3):415-20. PubMed ID: 8080724
    [Abstract] [Full Text] [Related]

  • 11. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
    Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR.
    Br J Cancer; 1992 Dec 15; 66(6):1109-15. PubMed ID: 1457352
    [Abstract] [Full Text] [Related]

  • 12. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.
    Cancer Chemother Pharmacol; 1994 Dec 15; 35(2):137-43. PubMed ID: 7987990
    [Abstract] [Full Text] [Related]

  • 13. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
    Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR.
    Cancer Res; 1992 Feb 15; 52(4):822-8. PubMed ID: 1737343
    [Abstract] [Full Text] [Related]

  • 14. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 15. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 16. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
    Kelland LR, Barnard CF, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR.
    Cancer Res; 1994 Nov 01; 54(21):5618-22. PubMed ID: 7923207
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA, Hosking LK, Hill BT.
    Cancer Res; 1991 Sep 01; 51(17):4557-64. PubMed ID: 1873800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.